Brief: China Isotope & Radiation Says Zhonghe Headway Obtained Clinical Trial Approval For BNCT Boron Drug
19/12/2025 17:41
Dec 19 (Reuters) - China Isotope & Radiation Corp 1763.HK: ZHONGHE HEADWAY OBTAINS CLINICAL TRIAL APPROVAL FOR BNCT BORON DRUG Further company coverage: 1763.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Isotope & Radiation
See all newsBrief: China Isotope & Radiation Corp's Unit Obatins Drug Registration Certificate For 50Mg Urea 13C Breath Test Kit
Brief: China Isotope & Radiation Proposes Appointment Of Li Penghui As Executive Director
Brief: China Isotope & Radiation Says CNGT Receives Confirmation Letter From U.S. FDA
Brief: China Isotope & Radiation Corp Says Board Approves Partnership Agreement With CNNC And Others
Brief: China Isotope & Radiation Corp Says Zhang Junqi Resigns As Executive Director